Table 2 Best overall response to treatment in the SOX+B-mab and SOX+C-mab population
Outcomes (RECIST v1.1) | SOX+B-mab (n = 22) | SOX+C-mab (n = 23) | Total (n = 45) |
|---|---|---|---|
Overall response rate (CR + PR) | 13 (59.1%) | 10 (43.5%) | 23 (51.1%), P = 0.29 |
Disease control rate (CR + PR + SD) | 20 (90.9%) | 21 (91.3%) | 41 (91.1%), P = 0.96 |
 Complete response (CR) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
 Partial response (PR) | 13 (59.1%) | 10 (43.5%) | 23 (51.1%) |
 Stable disease (SD) | 7 (31.8%) | 11 (47.8%) | 18 (40.0%) |
 Progressive disease (PD) | 1 (4.5%) | 1 (4.3%) | 2 (4.4%) |
 Could not be evaluated (NE) | 1 (4.5%) | 1 (4.3%) | 2 (4.4%) |
Conversion surgery | 4 (18.2%) | 3 (13.0%) | 7 (15.6%) |
 R0 resection | 4 (18.2%) | 1 (4.3%) | 5 (11.1%), P = 0.19 |
 R2 resection | 0 | 2 (8.7%) | 2 (4.4%) |